Skip to main content
      Understanding Comorbidities in RMD

      People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of

      Dr. John Cush RheumNow

      3 months 3 weeks ago
      Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
      All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR20

      Dr. John Cush RheumNow

      3 months 3 weeks ago
      All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.
      Day 1 Report from EULAR 2026

      The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session,

      Dr. John Cush RheumNow

      3 months 3 weeks ago
      Day 1 Report from EULAR 2026 The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
      #EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 3 weeks ago
      #EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃 https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w
      RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow a

      Dr. John Cush RheumNow

      3 months 3 weeks ago
      RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
      Digital Patient Education in RA
      Remember
      Babies of pts on chronic #immunosuppression with #SARDs

      ❎delay #vaccinations til 6/12
      For safety & to m

      Janet Pope Janetbirdope

      3 months 3 weeks ago
      Remember Babies of pts on chronic #immunosuppression with #SARDs ❎delay #vaccinations til 6/12 For safety & to mount sufficient response #rotovirus #vaccine is Ok before 6 months or vaccine is ineffective Pts w #SARDs need #COVID shots @RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY
      What’s new with the 2026 update of reco for vax in AIIRD?
      Vaccinate as soon as possible
      Non-live vaccines are safe
      Ho

      sheila RHEUMarampa

      3 months 3 weeks ago
      What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI
      #EULAR2026 #SARD #vaccination #recommendations
      I think 🤔
      ✅proactive➡️take responsibility
      ✅close gap
      ✅most

      Janet Pope Janetbirdope

      3 months 3 weeks ago
      #EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome
      He emphasizes the inportanc

      sheila RHEUMarampa

      3 months 3 weeks ago
      Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW
      B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
      ×